journal article·2026-05-08

Reversible Fe 3+ Coordination Drives Polydopamine Nanoparticle Assembly for High Iron Loading and Ferroptosis Selectivity

Sadman Sakib, Renjie Cui, Nesha May Andoy, Wanyan Liu, Franklin Perez, Anna Galang, Ruby May A. Sullan, Shan Zou

ACS Applied Nano Materials· Volume 9· Issue 18
Publisher page

Abstract

Polydopamine (PDA) nanomaterials are widely studied as biodegradable carriers for metal ions, particularly Fe³⁺, due to the strong affinity of catechol groups for iron. However, generating very small PDA nanoparticles with a high iron-loading capacity remains difficult. Here, we show that polymerizing dopamine at low concentration in alkaline buffer yields very small PDA nanoparticles (sPDA, ∼4 ± 2 nm) that rapidly assemble into nanoagglomerates (∼120 nm) upon exposure to Fe³⁺ (sPDA-Fe). These sPDA-Fe assemblies can accommodate high iron content (∼30 wt % Fe) and remain colloidally stable for days without the need for additional capping ligands. We further show that the reversible formation of sPDA-Fe is driven by coordination with Fe³⁺, as the nanoagglomerates readily disassemble in the presence of metal chelators. Finally, we demonstrate that sPDA-Fe nanoagglomerates can be utilized to deliver iron into four human cancer cell lines with distinct metabolic phenotypes. Unlike free iron, sPDA-Fe induces a dose-dependent loss of viability, consistent with ferroptotic cell death triggered by lipid peroxidation. Cell line-specific differences in pyroptotic or apoptotic signaling are also detected. Overall, sPDA-Fe acts as an efficient and tunable iron-delivery platform with a high loading capacity that can initiate iron-dependent cell death and may enable therapeutic applications targeting iron-sensitive mechanisms.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Polymer Surface Interaction Studies · Nanoparticle-Based Drug Delivery · Nanocluster Synthesis and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Metrology Research Centre, National Research Council Canada, 100 Sussex Drive, Ottawa, Ontario K1A 0R6, Canada

Department of Physical and Environmental Sciences, University of Toronto Scarborough, 1065 Military Trail, Toronto M1C 1A4, Canada

Department of Chemistry, University of Toronto, 80 St. George St., Toronto, Ontario M5S 1A1, Canada

Funding

Research Corporation for Science Advancement · Natural Sciences and Engineering Research Council of Canada

References (65)

Show source-provided references
1. 10.1021/acs.langmuir.6b0233110.1021/acs.langmuir.6b02331 ↗
2. 10.1021/acsnano.6b0550210.1021/acsnano.6b05502 ↗
3. 10.1002/smll.20190704210.1002/smll.201907042 ↗
4. 10.1021/acsbiomaterials.9b0046110.1021/acsbiomaterials.9b00461 ↗
5. 10.1039/D1AN02325J10.1039/D1AN02325J ↗
6. 10.1021/ja505412p10.1021/ja505412p ↗
7. 10.1021/bm400813810.1021/bm4008138 ↗
8. 10.1021/acsabm.9b0074710.1021/acsabm.9b00747 ↗
9. 10.1021/acs.langmuir.5c0047710.1021/acs.langmuir.5c00477 ↗
10. 10.1039/C5CP00932D10.1039/C5CP00932D ↗
11. 10.1038/s41392-022-01110-y10.1038/s41392-022-01110-y ↗
12. 10.1038/s41418-017-0012-410.1038/s41418-017-0012-4 ↗
13. 10.1111/j.1365-2567.2007.02587.x10.1111/j.1365-2567.2007.02587.x ↗
14. 10.1016/j.tcb.2013.07.00610.1016/j.tcb.2013.07.006 ↗
15. 10.1038/s41419-020-2298-210.1038/s41419-020-2298-2 ↗
16. 10.1016/j.cell.2017.09.02110.1016/j.cell.2017.09.021 ↗
17. 10.1038/cddis.2016.20810.1038/cddis.2016.208 ↗
18. 10.1093/rb/rbad00410.1093/rb/rbad004 ↗
19. 10.1021/acsami.7b0839210.1021/acsami.7b08392 ↗
20. 10.1021/la501560z10.1021/la501560z ↗
21. 10.1016/j.colsurfa.2020.12519610.1016/j.colsurfa.2020.125196 ↗
22. 10.1002/adfm.20200450310.1002/adfm.202004503 ↗
23. 10.1002/adfm.20120212710.1002/adfm.201202127 ↗
24. 10.1002/anie.20181176310.1002/anie.201811763 ↗
25. 10.1002/adfm.20120115610.1002/adfm.201201156 ↗
26. 10.1007/s12575-009-9008-x10.1007/s12575-009-9008-x ↗
27. 10.1021/acs.jpcb.8b1199410.1021/acs.jpcb.8b11994 ↗
28. 10.1021/acs.chemmater.7b0226210.1021/acs.chemmater.7b02262 ↗
29. 10.1073/pnas.100741610710.1073/pnas.1007416107 ↗
30. 10.1038/s41467-023-36303-810.1038/s41467-023-36303-8 ↗
31. 10.1002/admi.20210023910.1002/admi.202100239 ↗
32. 10.1021/ja00485a01810.1021/ja00485a018 ↗
33. 10.1007/s12013-009-9043-x10.1007/s12013-009-9043-x ↗
34. 10.1021/acsami.7b0966210.1021/acsami.7b09662 ↗
35. 10.1039/C9PY01372E10.1039/C9PY01372E ↗
36. 10.1021/la502660810.1021/la5026608 ↗
37. 10.1021/acsapm.4c0355110.1021/acsapm.4c03551 ↗
38. 10.1021/acs.est.5b0318910.1021/acs.est.5b03189 ↗
39. 10.1021/ic00160a01610.1021/ic00160a016 ↗
40. 10.1021/bm101281b10.1021/bm101281b ↗
41. 10.1021/la303855t10.1021/la303855t ↗
42. 10.1021/acsami.1c2406610.1021/acsami.1c24066 ↗
43. 10.1021/es902040u10.1021/es902040u ↗
44. 10.1180/claymin.1986.021.2.0810.1180/claymin.1986.021.2.08 ↗
45. 10.1039/D4NA00595C10.1039/D4NA00595C ↗
46. 10.1002/sia.198410.1002/sia.1984 ↗
47. 10.1021/ac50019a01610.1021/ac50019a016 ↗
48. 10.3390/ijms2001009510.3390/ijms20010095 ↗
49. 10.12659/MSM.91821610.12659/MSM.918216 ↗
50. 10.1016/j.bbamcr.2015.01.02110.1016/j.bbamcr.2015.01.021 ↗
51. 10.21769/BioProtoc.492910.21769/BioProtoc.4929 ↗
52. 10.1038/s41392-024-01769-510.1038/s41392-024-01769-5 ↗
53. 10.1002/adfm.20200857310.1002/adfm.202008573 ↗
54. 10.1038/nchembio.223910.1038/nchembio.2239 ↗
55. 10.3390/antiox1112244410.3390/antiox11122444 ↗
56. 10.1016/j.cell.2013.12.01010.1016/j.cell.2013.12.010 ↗
57. 10.1016/j.tcb.2015.10.01410.1016/j.tcb.2015.10.014 ↗
58. 10.1016/j.brainresbull.2024.11087810.1016/j.brainresbull.2024.110878 ↗
59. 10.1186/s12943-024-02217-210.1186/s12943-024-02217-2 ↗
60. 10.1038/s41419-023-05716-010.1038/s41419-023-05716-0 ↗
61. 10.18632/oncotarget.516210.18632/oncotarget.5162 ↗
62. 10.1016/j.ijbiomac.2024.13911810.1016/j.ijbiomac.2024.139118 ↗
63. 10.18632/oncotarget.2304610.18632/oncotarget.23046 ↗
64. 10.1111/j.1600-065X.2011.01044.x10.1111/j.1600-065X.2011.01044.x ↗
65. 10.1126/sciadv.aau943310.1126/sciadv.aau9433 ↗